Emergent BioSolutions (EBS) Research & Development (2011 - 2026)
Emergent BioSolutions (EBS) posted Research & Development of $9.2 million for Q2 2026, down 12.38% on a QoQ basis from $10.5 million in Q1 2026, and down 26.4% year-over-year from $12.5 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Research & Development (2011 - 2026) Analysis & Trends
Emergent BioSolutions has reported Research & Development for 16 years, with the latest figure at $9.2 million in Q2 2026.
- On a quarterly basis, Research & Development fell 26.4% year-over-year to $9.2 million in Q2 2026; TTM through Jun 2026 was $45.3 million, a 10.3% decrease from a year earlier, with the FY2025 full-year figure at $53.2 million, down 24.75% from the prior year.
- Research & Development was $9.2 million for Q2 2026 at Emergent BioSolutions, down from $10.5 million in the prior quarter.
- The five-year high for Research & Development was $49.8 million in Q2 2022, with the low at $9.1 million in Q4 2024.
- Average Research & Development over 5 years is $24.5 million, with a median of $15.2 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 69.05% in 2024, then surged 32.97% in 2025.
- Over 5 years, Research & Development stood at $47.0 million in 2022, then sank by 37.45% to $29.4 million in 2023, then tumbled by 69.05% to $9.1 million in 2024, then soared by 32.97% to $12.1 million in 2025, then dropped by 23.97% to $9.2 million in 2026.
- The last three Research & Development figures came in at $9.2 million (Q2 2026), $10.5 million (Q1 2026), and $12.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | 2.81 Bn |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | 2.96 Bn |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | -2.60 Bn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 612.28 Mn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 394.92 Mn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | 9.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.20 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 12.10 Mn |
| Sep 30, 2025 | 13.50 Mn |
| Jun 30, 2025 | 12.50 Mn |
| Mar 31, 2025 | 15.10 Mn |
| Dec 31, 2024 | 9.10 Mn |
| Sep 30, 2024 | 13.80 Mn |
| Jun 30, 2024 | 32.70 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Dec 31, 2023 | 29.40 Mn |
| Sep 30, 2023 | 15.30 Mn |
| Jun 30, 2023 | 26.00 Mn |
| Mar 31, 2023 | 40.70 Mn |
| Dec 31, 2022 | 47.00 Mn |
| Sep 30, 2022 | 42.20 Mn |
| Jun 30, 2022 | 49.80 Mn |
| Mar 31, 2022 | 46.40 Mn |
| Dec 31, 2021 | 38.20 Mn |
| Sep 30, 2021 | 49.60 Mn |
API Access
Emergent BioSolutions Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();